PureTech Health
500 Boylston Street
Suite 1600
Boston
Massachusetts
02116
United States
Tel: 617-482-2333
Fax: 617-482-3337
Website: http://www.puretechventures.com/
Email: info@puretechventures.com
166 articles about PureTech Health
-
PureTech Founded Entity Akili Collaborates with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to Study Digital Therapeutic AKL-T01 as Potential Treatment for Patients with COVID Brain Fog
4/7/2021
PureTech Health plc is pleased to note that its Founded Entity, Akili Interactive announced collaborations with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to evaluate Akili digital therapeutic AKL-T01 as a treatment for patients with cognitive dysfunction following COVID-19.
-
PureTech to Present at Two Upcoming Investor Conferences
4/7/2021
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that members of the management team will present at the following upcoming virtual investor conferences.
-
PureTech Announces Board Member Retirement
3/18/2021
PureTech Health plc, a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, announces that Stephen Muniz, Esq., will retire from his role as Chief Operating Officer and Corporate Secretary and will step down from the Board Of Directors, effective May 17, 2021.
-
PureTech: Notice of Results - Mar 15, 2021
3/15/2021
PureTech Health plc plans to publish its annual report and financial results on Thursday, April 15, 2021 at 2:00 AM EDT / 7:00 AM BST.
-
PureTech to Present at The Barclays Global Healthcare Conference
3/3/2021
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that George Farmer, Ph.D., its Chief Financial Officer, will present at the Barclays Global Healthcare Conference on Wednesday, March 10 th at 10:20 AM EST.
-
PureTech Founded Entity Karuna Therapeutics Announces Pricing of Public Offering of Common Stock
3/2/2021
PureTech Health plc (NASDAQ: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”), announced the pricing of an underwritten public offering of 2,083,334 shares of its common stock
-
PureTech Founded Entity Karuna Therapeutics Announces New England Journal of Medicine Publication of Data from EMERGENT-1 Phase 2 Trial Evaluating KarXT in Schizophrenia
2/25/2021
KarXT demonstrated statistically significant and clinically meaningful improvements in primary and key secondary efficacy measures compared with placebo
-
PureTech to Present at The SVB Leerink 10th Annual Global Healthcare Conference
2/18/2021
PureTech Health plc announced that Bharatt Chowrira, Ph.D., J.D., President and Chief of Business and Strategy, George Farmer, Ph.D., Chief Financial Officer, and Michael Chen, Ph.D., Head of Innovation, will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference on Friday, February 26th at 10:00 AM EST.
-
PureTech Receives Approximately $118 Million from Sale of Portion of Founded Entity Shares
2/10/2021
PureTech Health plc, a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, announced that it has sold 1 million shares of its Founded Entity, Karuna Therapeutics, through a block trade executed by Morgan Stanley & Co. LLC for cash consideration of approximately $118 million.
-
PureTech Founded Entity Vor Biopharma Closes Over $200M Initial Public Offering
2/10/2021
PureTech Health plc is pleased to note that its Founded Entity, Vor Biopharma, announced the closing of its previously announced initial public offering of 9,828,017 shares of its common stock, plus an additional 1,474,202 shares sold pursuant to the full option exercised by the underwriters, at a price to the public of $18.00 per share.
-
While the space is just beginning to emerge, therapies for long-haul COVID-19 patients are still very much an unmet need.
-
PureTech Founded Entity Vedanta Biosciences Appoints Mark Mullikin as Chief Financial Officer
2/8/2021
PureTech Health plc (LSE: PRTC, NASDAQ: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the appointment of Mark Mullikin as Chief Financial Officer.
-
PureTech Founded Entity Vor Biopharma Announces Pricing of Initial Public Offering
2/5/2021
PureTech Health plc (LSE: PRTC, NASDAQ: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Vor Biopharma, has announced the pricing of its initial public offering (IPO) of 9,828,017 shares of common stock at a public offering price of $18.00 per share
-
PureTech Adds Bharatt Chowrira, PureTech’s President and Chief of Business and Strategy, to Board of Directors
1/29/2021
PureTech Health plc, a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, announces the appointment of Bharatt Chowrira, Ph.D., J.D., to its Board of Directors as an executive director.
-
PureTech Founded Entity Follica Adds Two Leaders in Aesthetic Medicine and Dermatology to its Board of Directors
1/14/2021
PureTech Health plc is pleased to note that its Founded Entity, Follica, announced the appointment of two veteran biotech executives to its Board of Directors.
-
PureTech Announces the Appointment of George Farmer, Ph.D., as Chief Financial Officer
1/5/2021
PureTech Health plc, a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, announced that George Farmer, Ph.D., has been appointed Chief Financial Officer.
-
PureTech Founded Entity Follica Announces Pilot Study for Female Pattern Hair Loss Published in International Journal of Women’s Dermatology
12/9/2020
PureTech Health plc, a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Follica, announced the publication of a pilot study evaluating scalp skin disruption to promote hair growth in female pattern hair loss in International Journal of Women’s Dermatology.
-
PureTech Initiates Phase 2 trial of LYT-100 (Deupirfenidone) in Long COVID Respiratory Complications and Related Sequelae
12/3/2020
COVID-19 survivors may be at risk for persistent complications, a condition referred to as Long COVID or Long Haul COVID LYT-100, an anti-fibrotic and anti-inflammatory agent, holds potential for treating inflammation and fibrosis implicated in a range of respiratory conditions, including those associated with COVID-19
-
PureTech to Host Virtual R&D Day for Investors on December 11, 2020
11/30/2020
PureTech management to share research and clinical strategies for leveraging leadership in the lymphatic system and related immunology with the potential to deliver highly differentiated medicines
-
PureTech Founded Entity Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to its Board of Directors
11/24/2020
PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Vedanta Biosciences, t